Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to ...

Cobas Liat, we just recently announced the menu expansion ... In pathology, we will have a major update to the Roche Digital Pathology platform with enhanced image management, a fully redesigned ...

Tests broaden access to accurate, easy-to-use diagnostics for patients in a decentralised setting Roche has been granted US ...

Roche reported robust financial performance for the fourth quarter of 2024, with significant growth in both sales and core operating profit. The company's strategic focus on innovation and ...

Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver for its cobas liat ...

Basel, 22 January 2025 - Roche (SIX: RO, ROG ... Laboratory Improvement Amendments of 1988 (CLIA) waiver for its cobas® liat sexually transmitted infection (STI) multiplex assay panels.

Roche has obtained U.S. government green lights allowing its point-of-care testing system to be used to screen for multiple sexually transmitted infections from a single sample. The company’s ...

Roche has received 510(k) clearance with a Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver from the US Food and Drug Administration (FDA) for its cobas liat sexually transmitted ...

Roche announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver for its cobas liat sexually transmitted ...

Basel, 22 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance and Clinical Laboratory Improvement Amendments ...